This study is for patients with mantle cell lymphoma (MCL), a type of cancer that affects white blood cells. The research compares two treatments: rituximab, a medicine that helps stop cancer cells from growing, and stem cell transplant, a process where healthy blood cells are returned to the body after chemotherapy. The study looks at how well patients do with either treatment alone or both together.

Key Points:

• The study lasts for up to 10 years, with regular follow-up visits every 3 to 6 months.
• Participants may receive rituximab with or without undergoing a stem cell transplant.
• Risks include potential side effects from treatments, but there is a possibility of improved cancer control.

Participants must meet certain health criteria, including specific blood tests and a confirmed diagnosis of mantle cell lymphoma. Women must not be pregnant or breastfeeding, and all participants need to use birth control or abstain from sex during the study. If you qualify and want to join, you’ll have medical check-ups and treatments as part of the study plan.